- First dosings completed at the Royal Adelaide Hospital in Australia
- Pre-clinical data suggests FT-104 has a potency and pharmacology similar to psilocybin
- Objectives of the Phase 1 study include characterization of the safety, tolerability, pharmacokinetics and pharmacodynamic effects of FT-104
- Field Trip Health is a global leader in the development and delivery of psychedelic therapies
- Field Trip (FTRP) was down 0.85 per cent trading at C$1.16 as of 1:01 pm EDT
Field Trip Health (FTRP) has announced the first successful dosings in the Phase 1 Clinical Study.
The study is entitled “A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single, Ascending, Subcutaneous Doses of FT-104 HCl In Healthy Volunteers.”
The study is being conducted at PARC Clinical Research at the Royal Adelaide Hospital in Australia.
Field Trip’s first molecule in development, FT-104, is a prodrug of 4-OH-DiPT, a synthetic serotonin-2A (5HT2A) agonist.
Pre-clinical data suggests FT-104 has a potency and pharmacology similar to psilocybin, but with a significantly shorter half-life of approximately three hours.
Based on the FT-104 pre-clinical profile projecting a reduced treatment burden, and promising results from the early psilocybin therapy studies1 conducted at leading academic centers, the company believes that FT-104 could provide a rapid, safe, and effective therapy for depression and other mental health conditions when delivered in conjunction with psychotherapy.
The key objectives of the Phase 1 study include characterization of the safety, tolerability, pharmacokinetics and pharmacodynamic effects of FT-104 over a range of doses.
Subjective measurements will include intensity, duration and feelings produced by the acute psychoactivity after administration of FT-104 or placebo.
The company anticipates reporting results from the study in Q4 2022.
Dr. Nathan Bryson, Field Trip’s Chief Scientific Officer, commented on the news.
“The first administration of a novel, proprietary molecule is a landmark step for our company and a key milestone in our progress to develop FT-104 as a therapeutic for depression. Already, we are planning to share our work and our vision on the development of FT-104 in treatment-resistant depression and postpartum depression with the FDA in order to obtain their guidance as we look toward Phase 2 studies in 2023.”
Field Trip (FTRP) was down 0.85 per cent trading at C$1.16 as of 1:01 pm EDT.
